These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Paediatric clinical trials: redressing the imbalance. Schreiner MS Nat Rev Drug Discov; 2003 Dec; 2(12):949-61. PubMed ID: 14654794 [No Abstract] [Full Text] [Related]
4. Conduct of drug trials in poor countries must improve. Richards T BMJ; 2005 Jun; 330(7506):1466. PubMed ID: 15976407 [No Abstract] [Full Text] [Related]
5. WHO and industry combine to form ethics body. Dickson D Nat Med; 2002 Jul; 8(7):645. PubMed ID: 12091885 [No Abstract] [Full Text] [Related]
6. International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice. Food and Drug Administration, HHS Fed Regist; 2005 Oct; 70(202):61134-5. PubMed ID: 16237860 [TBL] [Abstract][Full Text] [Related]
7. Safety in clinical trials. Wallander MA Scand J Prim Health Care Suppl; 1990; 1():89-91. PubMed ID: 2100372 [TBL] [Abstract][Full Text] [Related]
8. [How to read reports on clinical trials of drugs. I]. Horácek J Cas Lek Cesk; 1986 Jul; 125(27):831-4. PubMed ID: 3731218 [No Abstract] [Full Text] [Related]
9. [Evaluation of the various phases of a clinical trial]. von Eickstedt KW MMW Munch Med Wochenschr; 1983 May; Suppl 1():S21-5. PubMed ID: 6408427 [No Abstract] [Full Text] [Related]
10. Committee for Medicinal Products for Human Use (CHMP) guideline on Data Monitoring Committees. ; ; Stat Med; 2006 May; 25(10):1639-45. PubMed ID: 16639775 [No Abstract] [Full Text] [Related]
11. Necessary evil? Boyce N New Sci; 2000 Sep; 167(2554):16-7. PubMed ID: 12549449 [No Abstract] [Full Text] [Related]
12. Controlled clinical trials in drug research: permission versus notification. Deutsch E Health Law Can; 1989; 9(3):71-3. PubMed ID: 10313021 [TBL] [Abstract][Full Text] [Related]
13. [The drug commission of German physicians and phase IV screening]. Ochsenfahrt H MMW Munch Med Wochenschr; 1983 Oct; 125(42):929-32. PubMed ID: 6417498 [No Abstract] [Full Text] [Related]
14. Tripartite meeting. Paediatric regulatory guidelines: do they help in optimizing dose selection for children? Baber NS Br J Clin Pharmacol; 2005 Jun; 59(6):660-2. PubMed ID: 15948928 [No Abstract] [Full Text] [Related]
16. Committee for Medicinal Products for Human Use (CHMP) guideline on the choice of the non-inferiority margin. ; ; Stat Med; 2006 May; 25(10):1628-38. PubMed ID: 16639773 [No Abstract] [Full Text] [Related]
17. FDA cracks down on labeling, initiates trial result reporting. Osborne R; Waltz E Nat Biotechnol; 2008 Nov; 26(11):1203-4. PubMed ID: 18997742 [No Abstract] [Full Text] [Related]
18. Drug assays in the assessment of the clinical value and safety of new compounds. Campbell DB Contemp Issues Clin Biochem; 1985; 3():33-60. PubMed ID: 3915972 [No Abstract] [Full Text] [Related]
19. Dose-ranging in clinical trials: rationale and proposed use with placebo or positive controls. Freston JW Am J Gastroenterol; 1986 May; 81(5):307-11. PubMed ID: 3706243 [TBL] [Abstract][Full Text] [Related]
20. Characteriation of clinical data packages using foreign data in new drug applications in Japan. Tanaka M; Nagata T Clin Pharmacol Ther; 2008 Sep; 84(3):340-6. PubMed ID: 17786162 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]